# A Phase II Study of Zuberitamab Injection in Patients With Primary Membranous Nephropathy

> **NCT06642909** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **BioRay Pharmaceutical Co., Ltd.** · enrollment: 135 (estimated)

## Conditions studied

- Primary Membranous Nephropathy

## Interventions

- **DRUG:** Zuberitamab 600mg
- **DRUG:** Zuberitamab 1000mg
- **DRUG:** cyclosporine

## Key facts

- **NCT ID:** NCT06642909
- **Lead sponsor:** BioRay Pharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2024-11-13
- **Primary completion:** 2027-03-31
- **Final completion:** 2027-05-10
- **Target enrollment:** 135 (ESTIMATED)
- **Last updated:** 2025-11-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06642909

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06642909, "A Phase II Study of Zuberitamab Injection in Patients With Primary Membranous Nephropathy". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT06642909. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*